Desidustat

Cat. No.:	HY-103227
CAS No.:	1616690-16-4
Molecular Formula:	$C_{16}H_{16}N_2O_6$
Molecular Weight:	332.31
Target:	HIF/HIF Prolyl-Hydroxylase
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 10 mg/mL (30.09 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.0092 mL	15.0462 mL	30.0924 mL
	5 mM	0.6018 mL	3.0092 mL	6.0185 mL
	10 mM	0.3009 mL	1.5046 mL	3.0092 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 1 mg/mL (3.01 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 1 mg/mL (3.01 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Desidustat is an orally active HIF hydroxylase inhibitor. Desidustat can be used for the research of various disorders including anemia of different types and conditions associated with ischemia/hypoxia[1].

In Vivo

Desidustat (oral; 10-100 mg/kg) has good efficacy in vivo[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57 Mice[1]
Dosage:	10, 30, 50, 100 mg/kg;

	20 mg /kg
Administration:	oral gavage; oral, once, daily, for 7 days
Result:	Significant increased the level of EPO and Hb.

CUSTOMER VALIDATION

- Drug Test Anal. 2020 Aug 27.
- J Anal Toxicol. 2020 May 20;bkaa055.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Ranjit C, et al. Novel quinolone derivatives. Patent. WO2014102818A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA